Tankyrase inhibition in personalized cancer medicine – defining patient inclusion criteria
- Prosjektnummer
- 2015012
- Ansvarlig person
- Stefan Krauss
- Institusjon
- Oslo universitetssykehus HF
- Prosjektkategori
- Doktorgradsstipend
- Helsekategori
- Cancer
- Forskningsaktivitet
- 4. Detection and Diagnosis, 5. Treatment Developement
TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting β-CATENIN and AKT Signaling in Colorectal Cancer.
Mol Cancer Res 2018 03;16(3):543-553. Epub 2017 des 8
PMID: 29222171 - Inngår i doktorgradsavhandlingen
Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.
J Med Chem 2017 Dec 28;60(24):10013-10025. Epub 2017 des 8
PMID: 29155568
The PARsylation activity of tankyrase in adipose tissue modulates systemic glucose metabolism in mice.
Diabetologia 2016 Mar;59(3):582-91. Epub 2015 des 2
PMID: 26631215
Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes.
Mol Cancer Res 2015 Nov;13(11):1487-501. Epub 2015 jun 29
PMID: 26124443
Expression profiling of wild type and ß-catenin gene disrupted human BxPC-3 pancreatic adenocarcinoma cells.
Genom Data 2015 Jun;4():150-2. Epub 2015 apr 15
PMID: 26484203
Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment.
PLoS One 2015;10(4):e0123684. Epub 2015 apr 10
PMID: 25860483
Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models
Under revision, 2019 -Inngår i doktorgradsavhandlingen
Identification of sensitivity and resistance response signatures for tankyrase inhibitor treatment of cancer
Submission, 2019 -Inngår i doktorgradsavhandlingen
- Jo Waaler Medveileder
- Line Mygland Doktorgradsstipendiat (finansiert av denne bevilgning)
- Line Mygeland Doktorgradsstipendiat
- Stefan Krauss Prosjektleder
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport